Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH is the German affiliate within the sanofi-aventis group. With a workforce of 10,000 people - 1,900 of them in R&D - it is the leading player in the German R&D-based pharmaceutical industry. The site in Frankfurt is the biggest R&D site of the sanofi-aventis group. The activities at this site focus on three therapeutic areas: cardiovascular diseases, diabetes / metabolic diseases and thrombosis.
Sanofi-aventis Recherche & Dévelopement
Sanofi-aventis Recherche & Dévelopement group together more than 5,500 people working on 11 R&D sites in France. The main research activities center around the therapeutic areas of neurobiological diseases, oncology, internal medicine, cardiovascular diseases, thrombosis & angiogenesis and exploratory research.
Within the Drug Safety Evaluation department, the Exploratory Safety group aims at investigating mechanisms of toxicity of new drug candidates, applying early and exploratory toxicology to specific projects with particular focus on biomarkers, toxicogenomics, metabonomics, and toxicoproteomics using differential 2D-gels and SELDI technologies. For more information, please visit: www.sanofi-aventis.com